ISTH 2015


Toronto at night, Photo by Paul Bica

The ISTH 2015 Congress took place June 20-25 in Toronto, Ontario, Canada.


Inhibitors increase burden of hemophilia care

HT Staff Read Article
Published: 07/03/15

Father and son

When children with hemophilia develop inhibitors, their caregivers shoulder a greater burden, according to a pilot study. Researchers surveyed 40 subjects on the burden of caring for a child with hemophilia and found that inhibitor development significantly increased the burden of care. But other factors—such as the number of bleeds a child had experienced in the last 12 months—had no significant impact. [Read Article]

Pain problems prevalent in adults with hemophilia

HT Staff Read Article
Published: 07/02/15

Doctor with a clipboard

A survey of adult hemophilia patients suggests there is room for improvement in assessing and managing disease-related pain. Roughly 85% of patients surveyed for this study, known as P-FiQ, said they had experienced acute and/or chronic pain in the past 6 months. Although most patients had no trouble caring for themselves, the pain often had an impact on their daily lives, especially with regard to physical activity and overall mobility. [Read Article]

Extended-interval dosing appears safe, effective

HT Staff Read Article
Published: 07/01/15

Alprolix components
Photo courtesy of Biogen

Full results of a phase 3 study support extended-interval dosing with a recombinant factor IX Fc fusion protein (rFIXFc) over FIX products with a standard half-life, according to a speaker at the 2015 ISTH Congress. Kathelijn Fischer, MD, PhD, of the University Medical Center Utrecht in The Netherlands, reported results with rFIXFc, also known as eftrenonacog alfa (Alprolix), in children with severe hemophilia B who were enrolled on the KIDS B-LONG study. [Read Article]

Anticoagulant antidote effective in healthy volunteers

HT Staff Read Article
Published: 06/30/15

Intravenous infusion

An antidote to factor Xa inhibitors can safely reverse the anticoagulant effect of apixaban in healthy volunteers, results of the ANNEXA-A study suggest. The first part of this study showed that a bolus of the antidote, andexanet alfa, was effective. And none of the volunteers had serious adverse events, thrombotic events, or antibodies to factor X or Xa. In the second part of the study, researchers tested a bolus and a 2-hour infusion of andexanet alfa. [Read Article]

Long-term data support use of FVIII treatment

HT Staff Read Article
Published: 06/29/15

Antihemophilic factor

The antihemophilic factor turoctocog alfa is safe and effective long-term, according to interim data from the phase 3 guardian 2 trial. With more than 4 years of safety data, researchers have found turoctocog alfa to be well-tolerated in patients with hemophilia A. The median annualized bleeding rate for patients on prophylactic treatment was 1.56 bleeds per patient per year. For patients who received turoctocog alfa on demand, a single injection stopped all bleeds. [Read Article]

Nanobody can help treat acquired TTP

HT Staff Read Article
Published: 06/26/15

Micrograph showing TTP
Image by Erhabor Osaro

Adding the anti-von Willebrand factor nanobody caplacizumab to standard therapy can provide clinical benefits for patients with acquired thrombotic thrombocytopenic purpura (TTP), according to research presented at the 2015 ISTH Congress. In the phase 2 TITAN trial, patients who received caplacizumab and standard therapy had a significantly shorter time to platelet normalization than patients who received standard therapy and placebo. [Read Article]

CT after unexplained VTE unnecessary, study suggests

HT Staff Read Article
Published: 06/25/15

Patient undergoing CT scan
Photo by Angela Mary Butler

A CT scan of the abdomen and pelvis does not improve cancer detection in people with unexplained venous thromboembolism (VTE), results of the SOME trial suggest. “Unexplained blood clots have long been thought of as a possible early warning sign of cancer, with previous studies suggesting that up to 10% of patients with unexplained clots will be diagnosed with cancer within the year,” said Marc Carrier, MD, of Ottawa Hospital Research Institute. [Read Article]

Drug reverses anticoagulant effect of dabigatran

HT Staff Read Article
Published: 06/24/15

Interim results of a phase 3 study suggest idarucizumab, a humanized antibody fragment, can reverse the anticoagulant effect of dabigatran in real-world situations. In the RE-VERSE AD trial, idarucizumab normalized diluted thrombin time (dTT) and ecarin clotting time (ECT) in a majority of patients with uncontrolled or life-threatening bleeding complications and most patients who required emergency surgery or an invasive procedure. [Read Article]

Bridge therapy not necessary in AFib, team says

HT Staff Read Article
Published: 06/24/15

Warfarin tablets

Bridge anticoagulant therapy appears to be unnecessary in patients with atrial fibrillation (AFib) undergoing elective surgery, according to researchers. In the BRIDGE study, AFib patients who stopped all anticoagulant therapy before elective surgery had no higher risk of thrombosis and a lower risk of major bleeding than patients who were given bridge therapy with low-molecular weight heparin after stopping warfarin. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}